---
title: "Maridebart cafraglutide"
canonical_url: https://peptidelibrary.app/library/maridebart-cafraglutide
description: "Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Maridebart cafraglutide

Maridebart cafraglutide (also called MariTide or AMG 133) is an investigational GIP antagonist in the GLP-1 Agonist class. Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.

Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.

Also known as: MariTide, AMG 133.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational GIP antagonist / GLP-1 agonist antibody-peptide
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other. This is the opposite of the tirzepatide approach, which agonises both, and the fact that GIPR agonism and antagonism have each produced weight reduction in trials remains an unresolved question in incretin pharmacology. The antibody scaffold gives a long half-life supporting infrequent dosing. It is investigational.

Targets: GIP receptor, GLP-1 receptor.

Origin: Engineered monoclonal antibody–peptide conjugate.

## Properties

- Molecular formula: — (antibody–peptide conjugate; very high MW)
- Molecular weight: ≈145–154 kDa (conjugate; assay-dependent)
- CAS number: 2760218-55-9
- Half-life: Long (monthly or less frequent dosing in trials)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2025

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. 2025. Controlled human trial. Population: Adults with obesity without type 2 diabetes (n=465). Mean body-weight change at week 52 from -12.3% to -16.2% across groups, against -2.5% with placebo [Source](https://pubmed.ncbi.nlm.nih.gov/40549887/)
2. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. 2025. Controlled human trial. Population: Adults with obesity and type 2 diabetes (n=127). Mean body-weight change from -8.4% to -12.3% against -1.7% with placebo; HbA1c fell 1.2 to 1.6 percentage points [Source](https://pubmed.ncbi.nlm.nih.gov/40549887/)
3. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. 2024. Controlled human trial. Population: Participants with obesity (n not stated in the indexed abstract). Dose-dependent weight loss, maintained up to 150 days after the last dose in the multiple-dose cohorts [Source](https://pubmed.ncbi.nlm.nih.gov/38316982/)
4. NCT06858839 — Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. Human study (early or uncontrolled). Population: Adults with obesity or overweight without type 2 diabetes (n=3,853). Ongoing; no results posted. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT06858839)

### Registered trials

- [NCT06858839](https://clinicaltrials.gov/study/NCT06858839)

## Safety

Side effects: GI effects; Antibody-related reactions possible.

Risks: Not approved; WADA S0.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Maridebart cafraglutide has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Maridebart cafraglutide?

Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.

### How does Maridebart cafraglutide work?

Maridebart cafraglutide is an antibody-peptide conjugate with an unusual design: it antagonises the GIP receptor while activating the GLP-1 receptor. A monoclonal antibody against GIPR is conjugated to GLP-1 analog peptides, so one molecule blocks one incretin receptor and stimulates the other.

### Is Maridebart cafraglutide FDA approved?

No. Maridebart cafraglutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### Is Maridebart cafraglutide banned in sport?

Maridebart cafraglutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Maridebart cafraglutide?

Compounds most often compared with Maridebart cafraglutide include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial — N Engl J Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40549887/)
- [Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications — Antib Ther, 2026](https://pubmed.ncbi.nlm.nih.gov/42592044/)
- [A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings — Nat Metab, 2024](https://pubmed.ncbi.nlm.nih.gov/38316982/)
- [Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity — J Med Chem, 2026](https://pubmed.ncbi.nlm.nih.gov/41941715/)
- [Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply — N Engl J Med, 2025](https://pubmed.ncbi.nlm.nih.gov/41337724/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
